Middle East Tech Today
SEE OTHER BRANDS

The best science and technology news from the Middle East

Middle East Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.

Press releases published on May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b …

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

An oral presentation at ASCO …

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These data …

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

·        BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/ …

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) …

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer …

Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting

Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting

AMSTERDAM, May 22, 2025 (GLOBE NEWSWIRE) -- Avidicure, a biotechnology company pioneering an entirely new dual agonistic, multifunctional antibody modality with broad applicability in oncology, today announced its upcoming presentation at the 2025 American …

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, …

Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results

Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results

CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), an advanced electromagnetic (“EM”) heating company with highly scalable solutions for large industrial applications, today announced its …

ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis

ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis

-- Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment -- TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology …

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two …

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at …

COOFANDY Marks 10th Anniversary with Dual Silver Awards at Berlin and New York Product Design Competitions

COOFANDY Marks 10th Anniversary with Dual Silver Awards at Berlin and New York Product Design Competitions

New York, NY, May 22, 2025 (GLOBE NEWSWIRE) -- As COOFANDY celebrates its 10th anniversary in 2025, the brand has reached an exciting new milestone: The COOFANDY Men’s Short-Sleeve Casual Shirts have earned Silver Awards at both the 2025 Berlin Design …

A new passive income solution for 2025: Efficiently participate in Bitcoin and cryptocurrency mining with PairMiner

A new passive income solution for 2025: Efficiently participate in Bitcoin and cryptocurrency mining with PairMiner

Washington, D.C., USA, May 22, 2025 (GLOBE NEWSWIRE) -- PAIRMiner, an advanced platform offering mining power services. Recently, Bitcoin has made a strong comeback, with its price soaring and reigniting global investors' passion and confidence in …

Best Dogecoin & Bitcoin Mining Site of 2025: FioBit Launches the Most Profitable AI Cloud Miner to Help Crypto Investors Earn Faster

Best Dogecoin & Bitcoin Mining Site of 2025: FioBit Launches the Most Profitable AI Cloud Miner to Help Crypto Investors Earn Faster

Sydney, Australia, May 22, 2025 (GLOBE NEWSWIRE) -- As the cryptocurrency market continues to mature in 2025, cloud mining has emerged as a cornerstone for both beginners and experienced investors seeking passive income through Bitcoin(BTC)  and Dogecoin( …

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an …

Bank of Baroda UAE Partners with In-Solutions Global to Launch Jaywan Cards in UAE

Bank of Baroda UAE Partners with In-Solutions Global to Launch Jaywan Cards in UAE

DUBAI, UNITED ARAB EMIRATES, May 22, 2025 /⁨EINPresswire.com⁩/ -- JP Morgan-backed fintech venture, In-Solutions Global (ISG), has partnered with Bank of Baroda UAE to launch Jaywan Cards in the UAE. This collaboration reinforces ISG’s commitment to …

Maryna Karpenko Wins Top Industry Honors for Shaping Global Communication

Maryna Karpenko Wins Top Industry Honors for Shaping Global Communication

Image courtesy of Maryna Karpenko SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- Maryna Karpenko, a product designer at Meta, helps shape the future of global communication, earning her top industry recognition, including the MUSE Creative Award, Vega …

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to file its …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service